{"product_id":"abcam-ab315995","title":"Abcam, ab315995, Anti-HHLA2 antibody [EPR26395-88] - BSA and Azide free","description":"\u003cp\u003eSize: 100µg \/ 1mg\u003cbr\u003e\nRabbit Recombinant Monoclonal HHLA2 antibody. Carrier free. Suitable for IHC-P, WB, IP and reacts with Transfected cell line - Human, Human samples.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR26395-88,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:Yes,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:IP, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nab315995 is the carrier-free version of\u003cbr\u003e\nab315994\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003cbr\u003e\nConjugation ready\u003cbr\u003e\nOur carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.\u003cbr\u003e\nUse our\u003cbr\u003e\nconjugation kits\u003cbr\u003e\nfor antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.\u003cbr\u003e\nCompatibility\u003cbr\u003e\nThis product is compatible with the Maxpar\u003cbr\u003e\nAntibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar\u003cbr\u003e\nis a trademark of Fluidigm Canada Inc.\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nThe HHLA2 protein also known as Human endogenous retrovirus-H Long Terminal Repeat-Associating 2 plays a role in the immune response. This protein is part of the B7 family which are known for their involvement in immunomodulation. It has a molecular weight of approximately 30 kDa. HHLA2 is expressed in various tissues including the placenta kidneys intestines and lungs. Additionally HHLA2 is typically upregulated in some cancer tissues which suggests a potential role in tumor immunity.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nHHLA2 acts as a co-inhibitory molecule that modulates T cell activity functioning to suppress T cell proliferation and cytokine production. It engages in the immune checkpoint pathways which are critical for maintaining immune tolerance and preventing over-activation of the immune system. HHLA2 does not act alone but rather interacts with other B7 family proteins in these pathways. It influences CTLA-4 and PD-1 mediated pathways by modulating the immune checkpoints adjusting the immune response based on physiological needs.\u003cbr\u003e\nPathways\u003cbr\u003e\nHHLA2 fits into the immune checkpoint regulation pathways. It is known to modulate the PD-1\/PD-L1 pathway which is essential for T cell immune evasion in cancer cells. Through its interactions HHLA2 can impact the tumor microenvironment by influencing immune cell infiltration and activation which is a significant aspect of cancer progression and immune evasion strategies. It is also related to CTLA-4 regulatory pathways which play an important role in maintaining immune homeostasis by negatively regulating T cell activation.\u003cbr\u003e\nHHLA2 associates with cancer particularly certain solid tumors where its expression is increased suggesting its role in immune evasion. This association points to its potential as a therapeutic target for immunotherapy. HHLA2 is connected to proteins like PD-L1 and CTLA-4 which are already known targets in cancer therapy because of their roles in bypassing immune detection by tumors. Additionally its expression is linked to autoimmune diseases where dysregulation of immune checkpoints results in excessive immune cell activity against self-tissues.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46851415900329,"sku":"ab315995","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab315995","provider":"Iright","version":"1.0","type":"link"}